



(51) International Patent Classification:
C07K 5/065 (2006.01)

(21) International Application Number:
PCT/IL2023/050281

(22) International Filing Date:
16 March 2023 (16.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/321,202 18 March 2022 (18.03.2022) US

(71) Applicant: **NEURODERM, LTD.** [IL/IL]; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL).

(72) Inventors: **LAXER, Avital**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL). **GAZAL, Elana**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL). **TALHAMI, Alaa**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL).

(74) Agent: **FISHER, Michal** et al.; Fisher Friedman Ip Group, PO BOX 12352, 4673300 Hertzliya Pituach (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: LEVODOPA TYROSINE POLYMORPHS




FIGURE 1

(57) Abstract: The disclosure is in part directed to crystalline forms of ((S)-2-amino-3-(3,4- dihydroxyphenyl)propanoyl)-A-tyrosine and pharmaceutical compositions thereof.

[Continued on next page]

Published:

— with international search report (Art. 21(3))